Royalty Pharma (RPRX) Assets Average (2020 - 2026)

Royalty Pharma has disclosed Assets Average across 7 years of filings, most recently posting $19.7 billion for Q1 2026.

• Assets Average for Q1 2026 came in at $19.7 billion, up 10.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.7 billion (up 10.06% YoY), and the FY2025 annual result was $18.9 billion, up 9.36% from the prior year.
• Assets Average came in at $19.7 billion for Q1 2026 at Royalty Pharma, up from $19.5 billion in the prior quarter.
• In the past five years, Assets Average ranged from a high of $19.7 billion in Q1 2026 to a low of $16.1 billion in Q4 2023.
• The 5-year median for Assets Average is $17.6 billion (2022), against an average of $17.6 billion.
• Across the five-year window, Assets Average decreased 6.88% in 2023 and grew 12.49% in 2024, its largest moves.
• Royalty Pharma's Assets Average stood at $17.2 billion in 2022, then retreated by 6.52% to $16.1 billion in 2023, then grew by 12.49% to $18.1 billion in 2024, then gained by 7.45% to $19.5 billion in 2025, then climbed by 1.2% to $19.7 billion in 2026.
• The last three Assets Average figures came in at $19.7 billion (Q1 2026), $19.5 billion (Q4 2025), and $18.8 billion (Q3 2025), per Business Quant data.